Ramasastry Saira
Known title: DirectorCIK: 0001547959
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Vir Biotechnology Secures $1.875B Gilead Deal for Cancer Drug Candidates. Vir Biotechnology entered a $1.875 billion partnership with Gilead that includes an upfront cash payment and shares, plus up to $1.785 billion in milestone payments and royalties. The collaboration also covers three PRO‑XTEN dual‑masked T‑cell engager candidates for solid tumors, with one, VIR‑5500, receiving FDA Fast‑Track status for metastatic castration‑resistant prostate cancer. These developments expand Vir’s oncology pipeline and strengthen its relationship with a major biopharma partner.
Transaction History
| MIRM | ▼ Sell | Open Market | 3,977 | $398K | 6/1/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 3,977 | — | 5/29/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 2,000 | $47K | 5/15/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 2,000 | $219K | 5/15/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 2,000 | $47K | 4/15/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 2,000 | $194K | 4/15/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 2,000 | $47K | 3/16/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 2,000 | $182K | 3/16/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 2,000 | $47K | 2/13/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 2,000 | $204K | 2/13/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 2,000 | $47K | 1/15/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 2,000 | $182K | 1/15/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 5,000 | $118K | 12/22/2025 | View on chart |
| MIRM | ▼ Sell | Open Market | 5,000 | $400K | 12/22/2025 | View on chart |
| MIRM | ▼ Sell | Open Market | 1,000 | $70K | 12/18/2025 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 2,000 | $47K | 12/18/2025 | View on chart |
| MIRM | ▼ Sell | Open Market | 1,000 | $69K | 12/18/2025 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 17,000 | $400K | 9/8/2025 | View on chart |
| MIRM | ▼ Sell | Open Market | 17,000 | — | 9/8/2025 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 2,500 | $35K | 6/3/2025 | View on chart |
| MIRM | ▼ Sell | Open Market | 2,500 | $114K | 6/3/2025 | View on chart |
| MIRM | ▼ Sell | Open Market | 5,703 | $263K | 6/2/2025 | View on chart |
| VIR | ▲ Buy | Grant | 8,000 | $0 | 5/30/2025 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 5,703 | — | 5/29/2025 | View on chart |
| VIR | ▼ Sell | Open Market | 4,000 | $44K | 6/11/2024 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 5,000 | $71K | 6/5/2024 | View on chart |
| MIRM | ▼ Sell | Open Market | 5,000 | $128K | 6/5/2024 | View on chart |
| VIR | ▲ Buy | Grant | 8,000 | $0 | 5/30/2024 | View on chart |
| VIR | ▼ Sell | Open Market | 3,500 | $90K | 6/1/2023 | View on chart |
| VIR | ▲ Buy | Grant | 6,027 | $0 | 5/22/2023 | View on chart |
| VIR | ▲ Buy | Grant | 5,000 | $64K | 7/11/2022 | View on chart |
| VIR | ▼ Sell | Open Market | 5,000 | $150K | 7/11/2022 | View on chart |
| VIR | ▼ Sell | Open Market | 1,687 | $40K | 5/24/2022 | View on chart |
| VIR | ▲ Buy | Grant | 6,405 | $0 | 5/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Mirum Pharma's Brevlovitug Hits Phase III Endpoint in Hepatitis Delta
Mirum Pharmaceuticals announced that its drug Brevlovitug met the primary endpoint in a Phase III study for hepatitis delta. The result supports the drug’s potential to become a treatment option for a rare viral infection. The news may influence how investors view the company’s pipeline and future growth prospects.
Mirum Pharma's Brevlovitug Hits Phase III Endpoint in Hepatitis Delta. Mirum Pharmaceuticals announced that its drug Brevlovitug met the primary endpoint in a Phase III study for hepatitis delta. The result supports the drug’s potential to become a treatment option for a rare viral infection. The news may influence how investors view the company’s pipeline and future growth prospects.